Single-Dose Bioequivalence Study of Rivaroxaban-Containing Medicinal Products in Healthy Volunteers
Therapeutically, new oral anticoagulants (NOACs) are considered to be non-inferior or superior to vitamin K antagonists (warfarin). NOACs are included in current guidelines for the treatment of various cardiovascular diseases. Rivaroxaban medicinal products have been shown to effectively fight throm...
Saved in:
Main Authors: | G. N. Gildeeva, A. A. Chaplenko, V. I. Yurkov, E. S. Stepanova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2022-10-01
|
Series: | Безопасность и риск фармакотерапии |
Subjects: | |
Online Access: | https://www.risksafety.ru/jour/article/view/316 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics and bioequivalence of the generic and original dabigatran etexilate after a single dose in healthy volunteers
by: V. B. Vasilyuk, et al.
Published: (2024-10-01) -
Pharmacokinetic and bioequivalence study of Telzap® Plus fixed-dose combination compared with MikardisPlus® in healthy volunteers after single administration
by: A. L. Khokhlov, et al.
Published: (2023-01-01) -
BIOEQUIVALENCE STUDY OF GENERIC MOLNUPIRAVIR IN HEALTHY VOLUNTEERS
by: V. B. Vasilyuk, et al.
Published: (2023-02-01) -
Bioequivalence study of generic nirmatrelvir in healthy volunteers
by: R. A. Oseshnyuk, et al.
Published: (2023-05-01) -
Pharmacokinetic and bioequivalence study of Telzap® in comparison with Mikardis® in healthy subjects after single administrationl
by: A. L. Khokhlov, et al.
Published: (2023-01-01)